Prostaglandins and cannabis—V. Identification of p-vinylphenol as a potent inhibitor of prostaglandin synthesis

Taylor, Pamela; El‐Feraly, Farouk S.; Turner, Carlton E.

doi:10.1016/0006-2952(76)90057-5

Cited by 17 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, CBD was shown to reduce joint inflammation in a murine model of collagen induced arthritis [Malfait et al, 2000]. Volatile oil components of the plant suppress cyclooxygenase‐1 (COX‐1) activity [Burstein et al, 1975, Burstein et al, 1976], and pyrolysis products of CBD exhibit activity in COX‐1 suppression assays [Spronck et al, 1978]. Since CBD is usually the most abundant nonpsychoactive cannabinoid in the plant, these pyrolysis products may add to the therapeutic properties of smoked marijuana.…”

mentioning

confidence: 99%

Prospects for cannabinoids as anti‐inflammatory agents

Zurier

2002

J of Cellular Biochemistry

View full text Add to dashboard Cite

The marijuana plant (Cannabis sativa) and preparations derived from it have been used for medicinal purposes for thousands of years. It is likely that the therapeutic benefits of smoked marijuana are due to some combination of its more than 60 cannabinoids and 200-250 non-cannabinoid constituents. Several marijuana constituents, the carboxylic acid metabolites of tetrahydrocannabinol, and synthetic analogs are free of cannabimimetic central nervous system activity, do not produce behavioral changes in humans, and are effective antiinflammatory and analgesic agents. One cannabinoid acid in particular, ajulemic acid, has been studied extensively in in vitro systems and animal models of inflammation and immune responses. This commentary reviews a portion of the work done by investigators interested in separating the medicinal properties of marijuana from its psychoactive effects. Understanding the mechanisms of the therapeutic effects of nonpsychoactive cannabinoids should lead to development of safe effective treatment for several diseases, and may render moot the debate about "medical marijuana".

show abstract

mentioning

confidence: 99%

Prospects for cannabinoids as anti‐inflammatory agents

Zurier

2002

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…CBD does reduce production of the proinflammatory cytokine TNF‐a and induces reduction of fatty acid amino‐ hydrolase (FAAH) activity, thereby increasing production of anandamide, an anti‐inflammatory endocannabinoid. Volatile oil components of Cannabis sativa suppress COX1 activity (13, 14), and pyrolysis products of CBD exhibit activity in COX‐1‐suppression assays (15). Several of the most abundant cannabinoid and noncannabinoid constituents of the plant are not psychoactive (16).…”

Section: Cannabis Constituentsmentioning

confidence: 99%

Cannabinoids, inflammation, and fibrosis

Zurier

Burstein

2016

FASEB j.

View full text Add to dashboard Cite

Cannabinoids apparently act on inflammation through mechanisms different from those of agents such as nonsteroidal anti-inflammatory drugs (NSAIDs). As a class, the cannabinoids are generally free from the adverse effects associated with NSAIDs. Their clinical development thus provides a new approach to treatment of diseases characterized by acute and chronic inflammation and fibrosis. A concise survey of the anti-inflammatory actions of the phytocannabinoids Δ-tetrahydrocannabinol (THC), cannabidiol, cannabichromene, and cannabinol is presented. Mention is also made of the noncannabinoid plant components and pyrolysis products, followed by a discussion of 3 synthetic preparations-Cesamet (nabilone; Meda Pharmaceuticals, Somerset, NJ, USA), Marinol (dronabinol; THC; AbbVie, Inc., North Chicago, IL, USA), and Sativex (Cannabis extract; GW Pharmaceuticals, Cambridge United Kingdom)-that have anti-inflammatory effects. A fourth synthetic cannabinoid, ajulemic acid (AJA; CT-3; Resunab; Corbus Pharmaceuticals, Norwood, MA, USA), is discussed in greater detail because it represents the most recent advance in this area and is currently undergoing 3 phase 2 clinical trials by Corbus Pharmaceuticals. The endogenous cannabinoids, including the closely related lipoamino acids, are then discussed. The review concludes with a presentation of a possible mechanism for the anti-inflammatory and antifibrotic actions of these substances. Thus, several cannabinoids may be considered candidates for development as anti-inflammatory and antifibrotic agents. Of special interest is their possible use for treatment of chronic inflammation, a major unmet medical need.-Zurier, R. B., Burstein, S. H. Cannabinoids, inflammation, and fibrosis.

show abstract

“…Phenolics. /?-Coumaric, p-hydroxybenzoic and vanillic acids ; and p-vinylphenol (probably an artefact) (Burstein et al, 1976).…”

Section: Monoterpenoid Chromenesmentioning

confidence: 99%

Ethnomedical, Botanical and Phytochemical Aspects of Natural Hallucinogens

Schultes¹,

Farnsworth²

1980

Botanical Museum Leaflets, Harvard University

View full text Add to dashboard Cite

More than 200 species and/ or varieties of higher plants, as well as numerous species of basidiomycetes, are reported in the literature to have been used for their hallucinatory and/ or euphoriant effects. Due to a paucity of research, only a few of these have been confirmed as definitely hallucinogenic in man or animals. This article reviews all of those plants now known to have a scientific basis for producing hallucinogenic effects in man or for which reliable ethnobotanical data are available to indicate that they could be hallucinogenic. Those plants alleged to be hallucinatory, but where substantive proof of this effect may be lacking, are summarily included for completeness arid in the hope of stimulating investigation.The hallucinogens of higher plant origin alone are found in 146 genera in more than 50 families. In virtually every instance in which the active constituents are known, their chemical skeletons are unique to a specific genus or to a very closely related genus.It is interesting to note that of more than 200 species of hallucinogenic plants only two are legally prohibited from use in the United States by Federal law: Cannabis sativa and Tabernanthe Iboga. Two or three others are illegal in a few states.

show abstract

Prostaglandins and cannabis—V. Identification of p-vinylphenol as a potent inhibitor of prostaglandin synthesis

Cited by 17 publications

References 7 publications

Prospects for cannabinoids as anti‐inflammatory agents

Prospects for cannabinoids as anti‐inflammatory agents

Cannabinoids, inflammation, and fibrosis

Ethnomedical, Botanical and Phytochemical Aspects of Natural Hallucinogens

Contact Info

Product

Resources

About